Links

src/contents/Human Practices/Conclisuin.tsx

@@ -10,7 +10,7 @@ export function HPconclusion(){
                 <H5 text="Human Practices Integration "/>
                 <p>From the start, we prioritized engaging with CF patients, making sure that our project aligned with both their needs and scientific expectations. Early input from Max Beckmann, a CF patient and friend of our team, guided key design decisions, such as our focus on lung-targeted gene therapy. His insights also shaped aspects like hygiene protocols for immunocompromised patients and the portrayal of CF in our outreach materials. Max’s ongoing feedback provided invaluable emotional insight, helping us ground the project in the real-world experiences of CF patients.</p>
                 <H5 text="Stakeholder Engagement "/>
-                <p>We consulted with medical professionals like Olariu Timeline <a onClick={() => goToPagesAndOpenTab('olariu', '')}>Dr. Olariu </a>  who emphasized the importance of early diagnosis and mental health support in CF treatment. These insights led us to integrate mental health considerations into our therapy design and focus on reducing racial and global disparities in CF care. Physiotherapist <a onClick={() => goToPagesAndOpenTab('westhoffinv', '')}>Katrin Westhoff</a>  highlighted the need for a user-friendly inhalation-based therapy for younger patients, validating our direction towards creating accessible treatments. </p>
+                <p>We consulted with medical professionals like <a onClick={() => goToPagesAndOpenTab('olariu', '')}>Dr. Olariu </a>  who emphasized the importance of early diagnosis and mental health support in CF treatment. These insights led us to integrate mental health considerations into our therapy design and focus on reducing racial and global disparities in CF care. Physiotherapist <a onClick={() => goToPagesAndOpenTab('westhoffinv', '')}>Katrin Westhoff</a>  highlighted the need for a user-friendly inhalation-based therapy for younger patients, validating our direction towards creating accessible treatments. </p>
                 <H5 text="Ethical, Legal, and Regulatory Considerations "/>
                 <p>Collaboration with regulatory experts, such as <a onClick={() => goToPagesAndOpenTab('berens', '')}> Dr. Eva-Maria Berens </a> , ensured our work adhered to ethical and legal standards, particularly in patient consent and biosafety protocols. Through feedback from legal and bioethics committees, we refined our consent processes and improved our management of personal data, ensuring our project complied with both German and international regulations. </p>
                 <H5 text="Technical and Scientific Adaptations "/>
@@ -448,11 +448,12 @@ function AnalyseBerens(){
     ) 
  }
 function AnalyseWeber(){
+    const {goToPagesAndOpenTab} = useNavigation();
     return(
      <Collapsible title="Prof. Dr. Weber and Dr. Große-Onnebrink " id="weberanalyseC">
          <p>Prof. Weber and Dr. Große-Onnebrink emphasized the potential of targeting ionocytes due to their crucial role in CFTR expression while highlighting the challenges of accessing these cells and penetrating the mucus barrier. Additionally, they suggested using an Ussing chamber to assess CFTR function, although they noted its limitations, and recommended exploring chitosan-based nanoparticles as a safer alternative to PEG-lipid systems. </p>
          <p>In response to their insights, we continued to explore ionocytes but expanded our focus to include other cell types to enhance testing flexibility. We further investigated chitosan-based nanoparticles and optimized their size for better lung penetration. We plan to utilize the Ussing chamber for CFTR measurements and are also considering patch clamping for detailed transfection analysis. </p>
-         <p>Prof. Weber highlighted the innovative aspects of our project, particularly regarding cell culture methods. He advised us to consider the ethical and legal implications, which led us to consult with the head of the ethics committee at the University of Bielefeld, Dr. Berens[Link]. Due to legal concerns, the committee is unable to support our project directly, as they have an interest in developing their own Chitosan LNPs, which conflicts with the open-source nature of the iGEM competition. Nevertheless, they provided us with valuable information up to that point, guiding our understanding and approach to the project. </p>
+         <p>Prof. Weber highlighted the innovative aspects of our project, particularly regarding cell culture methods. He advised us to consider the ethical and legal implications, which led us to consult with the head of the ethics committee at the University of Bielefeld, <a onClick={() => goToPagesAndOpenTab('berens', '/human-practices')}>Dr. Eva-Maria Berens</a>. Due to legal concerns, the committee is unable to support our project directly, as they have an interest in developing their own Chitosan LNPs, which conflicts with the open-source nature of the iGEM competition. Nevertheless, they provided us with valuable information up to that point, guiding our understanding and approach to the project. </p>
          <figure>
             <div className="row">
             <div className="col">
@@ -552,7 +553,7 @@ function AnalyseKolonko(){
 function AnalyseRnhale(){
     return(
      <Collapsible title="Dr. Benjamin Winkeljann – RNhale, Industry Expert & Researcher " id="rnhaleanalyseC">
-         <p>Dr. Benjamin Winkeljann from RNhale[Link] provided crucial technical guidance that significantly enhanced our project. His expertise in spray-dried lipid nanoparticles (LNPs) allowed us to improve the shelf-life and scalability of our formulations. We learned about the limitations of CF therapies regarding international access, cost, and availability, which highlighted the need for sustainable solutions. </p>
+         <p>Dr. Benjamin Winkeljann from <a href="https://rnhale.com/" >Rnhale</a> provided crucial technical guidance that significantly enhanced our project. His expertise in spray-dried lipid nanoparticles (LNPs) allowed us to improve the shelf-life and scalability of our formulations. We learned about the limitations of CF therapies regarding international access, cost, and availability, which highlighted the need for sustainable solutions. </p>
         <p>We discovered that spray drying is an effective method for stabilizing LNPs, enabling transport without refrigeration — a more environmentally friendly approach that reduces energy consumption.  </p>
         <p>Our close collaboration with RNhale will continue even after the wiki freeze, focusing on producing spray-dried LNPs and testing them on our primary cultures. We are also investigating how to enhance the stability of LNPs, particularly in protecting RNA from heat damage, and are seeking experts in chitosan for further support. </p>
         <p>During discussions with a young startup entrepreneur, we explored the possibility of pursuing an entrepreneurship-oriented[Link] project but ultimately decided to focus on a human-centered approach that prioritizes the needs of CF patients over cost-driven industrial pathways. </p>